MedTrace Logo

Nicotinamide in Hemodialysis Patients With Hyperphosphatemia

NCT01200784 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 252

Last updated 2012-01-18

No results posted yet for this study

Summary

Study hypothesis: Nicotinamide inhibits gastrointestinal phosphate absorption and serum phosphate levels of dialysis patients in a dose dependent manner.

Conditions

Interventions

DRUG

Nicotinamide

dosage

Sponsors & Collaborators

  • Medice Arzneimittel Pütter GmbH & Co KG

    lead INDUSTRY

Principal Investigators

  • Walter Zidek, Prof. Dr. · Charité Berlin, Campus Benjamin Franklin, Innere Medizinische Klinik IV WE 28

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2011-06-30
Completion
2011-07-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01200784 on ClinicalTrials.gov